Development of a Broth Microdilution Method for Exebacase Susceptibility Testing-Reference-Cited by-同舟云学术

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing

Published:2021-06-17 Issue:7 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Oh Jun T.¹,Ambler Jane E.¹,Cassino Cara¹,Schuch Raymond¹^ORCID

Affiliation:

1. ContraFect Corporation, Yonkers, New York, USA

Abstract

Exebacase (CF-301) belongs to a new class of protein-based antibacterial agents, known as lysins (peptidoglycan hydrolases). Exebacase, a novel lysin with antistaphylococcal activity, is in phase 3 of clinical development.

Funder

ContraFect Corporation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02587-20

Reference30 articles.

1. Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments

2. Endolysins as Antimicrobials

3. Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus–Induced Murine Bacteremia

4. Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent

5. Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials;Expert Opinion on Investigational Drugs;2024-03-06

2. Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase;Microbiology Spectrum;2023-10-17

3. The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics;Microbiology Spectrum;2023-04-13

4. Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance;Frontiers in Microbiology;2022-03-03

5. Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections;Drugs in R&D;2022-02-17